Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1980 2
1981 5
1982 2
1983 1
1984 2
1986 1
1987 3
1991 1
1992 2
1993 1
1995 1
1997 2
1998 5
1999 1
2001 8
2002 2
2003 1
2004 2
2005 2
2006 1
2007 1
2008 6
2009 3
2010 1
2012 2
2013 1
2014 1
2015 1
2016 1
2017 2
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Leonardi CL, et al. Lancet. 2008 May 17;371(9625):1665-74. doi: 10.1016/S0140-6736(08)60725-4. Lancet. 2008. PMID: 18486739 Clinical Trial.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR; Phase 3 Tirbanibulin for Actinic Keratosis Group. Blauvelt A, et al. N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040. N Engl J Med. 2021. PMID: 33567191 Clinical Trial.
Erythema dyschromicum perstans.
Tschen JA, Tschen EA, McGavran MH. Tschen JA, et al. Among authors: tschen ea. J Am Acad Dermatol. 1980 Apr;2(4):295-302. doi: 10.1016/s0190-9622(80)80041-7. J Am Acad Dermatol. 1980. PMID: 6767758
Klippel-Trénaunay-Weber syndrome.
Nielsen JR, Tschen EH. Nielsen JR, et al. Among authors: tschen eh. Cutis. 1987 Jul;40(1):51-3. Cutis. 1987. PMID: 2822360 Review.
Contact urticaria to parabens.
Henry JC, Tschen EH, Becker LE. Henry JC, et al. Among authors: tschen eh. Arch Dermatol. 1979 Oct;115(10):1231-2. Arch Dermatol. 1979. PMID: 159667
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials.
Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Moore A, et al. Among authors: tschen e. J Drugs Dermatol. 2018 Sep 1;17(9):987-996. J Drugs Dermatol. 2018. PMID: 30235387 Clinical Trial.
69 results